tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Exact Sciences acquires Freenome colorectal cancer screening tests

Exact Sciences (EXAS) announced it has entered into an agreement to acquire exclusive rights in the United States to current and future versions of Freenome’s blood-based, single indication, colorectal cancer screening tests. Under the terms of the agreement, Freenome will receive $75M in cash payable by November 2025. Additional potential payments of up to $700M are based on the achievement of certain milestones for Freenome’s blood-based CRC screening tests.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1